The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Libmeldy autologous CD34+ cells encoding ARSA gene OrphanATMPAdditional monitoring | Orchard Therapeutics (Netherlands) B.V. | Leukodystrophy, Metachromatic | 🇪🇺 EU 2020-12-17 | Order → |
| Palforzia defatted powder of Arachis hypogaea L., semen (peanuts) Additional monitoring | Stallergenes | Peanut Hypersensitivity | 🇪🇺 EU 2020-12-17 | Order → |
| Rekambys rilpivirine Additional monitoring | Janssen-Cilag International NV | HIV Infections | 🇪🇺 EU 2020-12-17 | Order → |
| Vocabria cabotegravir Additional monitoring | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 2020-12-17 | Order → |
| Tecartus brexucabtagene autoleucel OrphanPRIMEATMP | Kite Pharma EU B.V. | Lymphoma, Mantle-Cell | 🇪🇺 EU 2020-12-14 | Order → |
| Leqvio inclisiran | Novartis Europharm Limited | Hypercholesterolemia; Dyslipidemias | 🇪🇺 EU 2020-12-09 | Order → |
| Trixeo Aerosphere formoterol;glycopyrronium bromide;budesonide | AstraZeneca AB | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2020-12-09 | Order → |
| Oxlumo lumasiran OrphanPRIME | Alnylam Netherlands B.V. | Hyperoxaluria, Primary | 🇪🇺 EU 2020-11-19 | Order → |
| MenQuadfi meningococcal group A, C, W-135 and Y conjugate vaccine | Sanofi Winthrop Industrie | Meningitis, Meningococcal | 🇪🇺 EU 2020-11-18 | Order → |
| Nyvepria pegfilgrastim Biosimilar | Pfizer Europe MA EEIG | 🇪🇺 EU 2020-11-18 | Order → | |
| Nyxthracis (previously Obiltoxaximab SFL) obiltoxaximab Exceptional circumstancesAdditional monitoring | SFL Pharmaceuticals Deutschland GmbH | Anthrax | 🇪🇺 EU 2020-11-18 | Order → |
| Exparel liposomal bupivacaine | Pacira Ireland Limited | Acute Pain | 🇪🇺 EU 2020-11-16 | Order → |
| Phelinun melphalan | Multiple Myeloma; Hodgkin Disease; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Neuroblastoma; Ovarian Neopl | 🇪🇺 EU 2020-11-16 | Order → | |
| Rivaroxaban Accord rivaroxaban Generic | Accord Healthcare S.L.U. | Acute Coronary Syndrome; Coronary Artery Disease; Peripheral Arterial Disease; Venous Thromboembolism; Stroke; Atrial Fibrillation; Pulmonary Embolism | 🇪🇺 EU 2020-11-16 | Order → |
| Supemtek Tetra (previously Supemtek) quadrivalent influenza vaccine (recombinant, prepared in cell culture) | Sanofi Winthrop Industrie | Influenza, Human | 🇪🇺 EU 2020-11-16 | Order → |
| Calquence acalabrutinib | AstraZeneca AB | Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2020-11-05 | Order → |
| Adakveo crizanlizumab ConditionalAdditional monitoring | Novartis Europharm Limited | Anemia, Sickle Cell | 🇪🇺 EU 2020-10-28 | Order → |
| Arikayce liposomal amikacin Orphan | Insmed Netherlands B.V. | Respiratory Tract Infections | 🇪🇺 EU 2020-10-27 | Order → |
| Ayvakyt avapritinib OrphanConditionalAdditional monitoring | Blueprint Medicines (Netherlands) B.V. | Gastrointestinal Stromal Tumors | 🇪🇺 EU 2020-09-24 | Order → |
| Equidacent bevacizumab BiosimilarAdditional monitoring | Centus Biotherapeutics Europe Limited | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2020-09-24 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.